Abecma Delivers Sustained Progression-Free Survival Versus S

At median follow-up of more than 30 months, Abecma maintained a 51% reduction in risk of disease progression or death with median PFS of 13.8 months compared with 4.4 months for standard regimensResponses were significantly improved with Abecma and continued to deepen over time with a complete response rate of 44% v...

Related Keywords

Israel , Canada , United Kingdom , Cambridge , Cambridgeshire , Spain , Switzerland , United States , Japan , American , Paula Rodriguez Otero , Sergio Giralt , Hemophagocytic Lymphohistiocytosis , Bristol Myers Squibb , Steve Bernstein , Anne Kerber , Oncologic Drugs Advisory Committee , Division Of Hematologic Malignancies , American Society Of Hematology , European Union , Department Of Hematology , Memorial Sloan Kettering Cancer Center , Nasdaq , Drug Administration , European Medicines Agency , Head Of Late Clinical Development , American Society , Annual Meeting , Oral Presentation , Clinica Universidad De Navarra , Late Clinical Development , Cell Therapy , Bristol Myers , Hematologic Malignancies , Memorial Sloan Kettering Cancer , Biologics License Application , Extended Follow Up , Poster Presentation , Important Safety Information , Macrophage Activation Syndrome , Sloan Kettering Cancer Center , Profit Share Agreement , Release Syndrome , Risk Evaluation , Mitigation Strategy , Igg Secondary Malignancies , Operate Machinery ,